Skip to Content

Intarcia to Announce Key ITCA 650 Phase 3 Findings and Other Data Presentations at Upcoming 75th Scientific Sessions of the American Diabetes Association in Boston

Intarcia to Announce Key ITCA 650 Phase 3 Findings and Other Data Presentations at Upcoming 75th Scientific Sessions of the American Diabetes Association in Boston

  • Presentations to include data from ITCA 650 pivotal Phase 3 FREEDOM-1 study, and FREEDOM-1 HBL (High Baseline) open-label study, as well as real-world data analyses on adherence, outcomes and economics of current type 2 diabetes treatment regimens.
  • Intarcia to host a Product Theater featuring discussion by leading experts on current issues and challenges resulting from poor adherence to therapy and lack of glycemic control in majority of diagnosed type 2 diabetes patients.

Boston, MA – June 3, 2015Intarcia Therapeutics, Inc. today announced its Company-sponsored presentations at the upcoming 75th Scientific Sessions of the American Diabetes Association taking place June 5th through June 9th at the Boston Convention and Exhibition Center. The presentations span pre-clinical, clinical and real-world analyses of the effects of currently marketed and investigational therapies on patients with type 2 diabetes, including Phase 3 clinical data of Intarcia’s late-stage clinical candidate, ITCA 650.

  • Saturday June 6, 2015 | Session 01-D: Clinical Therapeutics/New Technology—Non-Insulin Injectables
    Poster Presentation1107-P: “Efficacy and Tolerability of 39 Wks of ITCA 650 (Continuous Subcutaneous Exenatide) in Poorly Controlled T2DM with High Baseline A1c (>10%),” by Robert R. Henry, Julio Rosenstock, Douglas S. Denham, Prakash Prabhakar, Lise Kjems, Michelle Baron, will take place from 11:30 am - 1:30 pm ET in Poster Hall B.

    Poster presentation 1108-P: “Delivery of Exenatide by Subdermal Placement of ITCA 650 in a Nonclinical Model Demonstrates 1 Year of Continuous Exposure and Tolerability,” by Doris T. Zane, Lauren Thorner, Michelle Baron, Manisha Charan, Tracey Zoetis, Robert M. Fielding, Chris N. Papagiannis, Tom Alessi, will also take place from 11:30 am - 1:30 pm ET in Poster Hall B. Both of these posters are being included in the Guided Audio Poster Tour Session 3-CT-PT07:  GLP-1 Receptor Agonists – Delivery and Actions, taking place Sunday June 7, from 12:00 to 1:00 pm ET.

  • Sunday June 7, 2015 | Session 01-F: Clinical Therapeutics/New Technology—Pharmacologic Treatment of Complications
    Poster 135-LB: “Treatment, Adherence, and Change in A1c in Type 2 Diabetes (T2DM) with High (>10%) HbA1c,” by Ginger S. Carls, Christian Frois, Edward Tuttle, Michelle A. Baron, will be presented from 12:00 pm to 2:00 pm in Poster Hall B.

  • Sunday June 7, 2015 | Session 13: Health Care Delivery—Economics
    Poster 142-LB: “A Regimen-based Measure of Adherence and Costs Associated with Nonadherence to Type 2 Diabetes (T2DM) Medications,” by Ruo-ding Tan, Ginger S. Carls, Christian Frois, Edward Tuttle, will be presented from 12:00 pm to 2:00 pm in Poster Hall B.

  • Monday June 8, 2015 | Update on GLP-1 Receptor Agonists
    Oral Presentation 276 OR: “Clinical Impact of ITCA 650 in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled 39 Week Trial,” by Julio Rosenstock, M.D., Director of the Dallas Diabetes and Endocrine Center and a Clinical Professor of Medicine at the University of Texas Southwestern Medical School at Dallas, will be presented at 8:15 am ET in Room 258.

  • Monday June 8, 2015 | Product Theater #2
    Intarcia is sponsoring: Steven V. Edelman, MD, Clinical Professor of Medicine, University of California, San Diego, and Troy Ross, MSM, President & CEO Mid-America Coalition on Health Care, Overland Park, KS, discussing “Nonadherence & Glycemic Control: A Real-World Look at the Issues and Challenges We Face,” from 10:15 am to 11:00 am in Product Theater #2.

In addition, Intarcia announced the publication of abstract 2576-PO: “Uncontrolled T2DM Patients: Characteristics, Diabetes Therapy, and Outcomes,” by Christian Frois, Ruo-ding Tan, Ginger S. Carls, Edward Tuttle, Michelle A. Baron.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is an independent, privately held, biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once or twice yearly has the potential to ensure improved patient adherence and compliance, which is otherwise difficult to achieve in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is conducting a Phase 3 development program for type 2 diabetes that consists of four separate clinical trials, two of which have been completed. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic serious disorders in the field of diabetes, obesity and autoimmune diseases. For more information about Intarcia, please visit www.intarcia.com.

About ITCA 650
ITCA 650 is being developed for the treatment of type 2 diabetes, combining Intarcia’s proprietary technology platform involving a matchstick-size, miniature osmotic pump that is placed sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. If approved, ITCA 650 would represent the first injection-free GLP-1 therapy capable of delivering up to a full year of treatment from a single device placement. ITCA 650 is currently in a global Phase 3 clinical trial program called FREEDOM.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.

 

INVESTOR CONTACT

Intarcia Therapeutics, Inc.
James Ahlers
james.ahlers@intarcia.com
(510) 782-7800

MEDIA CONTACTS

Intarcia Therapeutics, Inc.
Paulina Bucko
paulina.bucko@intarcia.com
(857) 880-1442

Shaping the future:

Press Releases

Intarcia Appoints Thane Wettig as Chief Marketing Officer and Metabolic Franchise Head

Read More

Intarcia Provides Corporate Update

Read More

Intarcia Strengthens Board of Directors for Next Stage of Growth

Read More
MORE NEWS
Back to top